Contineum MS drug stumbles in mid-stage trial
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
The company will soon be launching a new portfolio of products in this segment
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
Millions of stroke survivors across the world may soon have a new defense
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
Subscribe To Our Newsletter & Stay Updated